Naftopidil Is Useful for the Treatment of Malignant Pleural Mesothelioma

被引:8
|
作者
Mikami, Koji [1 ]
Nagaya, Hisao [2 ]
Gotoh, Akinobu [2 ]
Kanno, Takeshi [3 ]
Tsuchiya, Ayako [3 ]
Nakano, Takashi [1 ]
Nishizaki, Tomoyuki [3 ]
机构
[1] Hyogo Coll Med, Dept Internal Med, Div Resp Med, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Inst Adv Med Sci, Lab Cell & Gene Therapy, Nishinomiya, Hyogo 6638501, Japan
[3] Hyogo Coll Med, Dept Physiol, Div Bioinformat, Nishinomiya, Hyogo 6638501, Japan
关键词
Naftopidil; Malignant pleural mesothelioma; Apoptosis; Tumor necrosis factor-alpha; FasL; Cancer therapy; ALPHA(1)-ADRENOCEPTOR ANTAGONIST; CANCER CELLS; PHASE-II; APOPTOSIS; PROSTATE; MULTICENTER; BEVACIZUMAB; CISPLATIN; GROWTH;
D O I
10.1159/000368050
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Naftopidil, an alpha(1)-adrenoceptor blocker, induced apoptosis of human malignant pleural mesothelioma NCI-H2052 cells. Naftopidil upregulated the expression of tumor necrosis factor-alpha (TNF-alpha) mRNA in these cells. Naftopidil, alternatively, increased FasL secretion from NCI-H2052 cells, without affecting the expression of FasL mRNA and protein, and activated caspase-3 and -8 in NCI-H2052 cells. Naftopidil drastically suppressed tumor growth in mice inoculated with these cells. The results of the present study indicate that naftopidil induces apoptosis of NCI-H2052 cells by upregulating the expression of TNF-alpha and stimulating the secretion of FasL, a ligand for the death receptor Fas, both to activate caspase-8 and the effector caspase-3, leading to the suppression of NCI-H2052 cell proliferation in vivo. This raises the possibility that naftopidil could be developed as an effective drug for the treatment of malignant pleural mesothelioma. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [1] Naftopidil Is Effective in the Treatment of Malignant Pleural Mesothelioma
    Mikami, Koji
    Kuribayashi, Kozo
    Ieki, Ryuji
    Terada, Takayuki
    Otsuki, Taiichiro
    Kamiya, Hitomi
    Masachika, Eriko
    Gotoh, Akinobu
    Nishizaki, Tomoyuki
    Nakano, Takashi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S749 - S749
  • [2] Treatment of malignant pleural mesothelioma
    Alolayan, Ashwaq
    Saadeddin, Ahmed
    Bamousa, Ahmed
    Jazieh, Abdul-Rahman
    ANNALS OF THORACIC MEDICINE, 2010, 5 (05) : S71 - S75
  • [3] Treatment of malignant pleural mesothelioma
    Rusch, VW
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 18 (04) : 363 - 373
  • [4] TRIMODALITY TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
    Sottero, T.
    Kusano, A.
    Truong, A.
    Laramore, G.
    Stelzer, K.
    Patel, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (01) : 228 - 228
  • [5] Malignant pleural mesothelioma: Diagnosis and treatment
    Delourme, J.
    Dhalluin, X.
    Cortot, A. B.
    Lafitte, J. -J.
    Scherpereel, A.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (01) : 26 - 35
  • [6] Pleuropneumonectomy in the treatment of malignant pleural mesothelioma
    Grondin, SC
    Sugarbaker, DJ
    CHEST, 1999, 116 (06) : 450S - 454S
  • [7] Multimodal treatment for malignant pleural mesothelioma
    Rintoul, Robert C.
    Treasure, Tom
    Macbeth, Fergus
    LANCET ONCOLOGY, 2015, 16 (16): : 1576 - 1577
  • [8] Surgical Treatment of Malignant Pleural Mesothelioma
    Andrew J. Kaufman
    Raja M. Flores
    Current Treatment Options in Oncology, 2011, 12
  • [9] Radiotherapy for the treatment of malignant pleural mesothelioma
    de Perrot, Marc
    Wu, Licun
    Wu, Matthew
    Cho, B. C. John
    LANCET ONCOLOGY, 2017, 18 (09): : E532 - E542
  • [10] Multidisciplinary treatment of malignant pleural mesothelioma
    Ceresoli, Giovanni Luca
    Gridelli, Cesare
    Santoro, Armando
    ONCOLOGIST, 2007, 12 (07): : 850 - 863